daily links header


8:00 am – 9:00 am

Concurrent Session 33:
VAD Support for Children (Sapphire D)

Concurrent Session 34:
Impact of Gender and Race on Outcomes after Heart Transplant (Sapphire AE)

Concurrent Session 35:
Doing More with LES in Lung Transplantation (Sapphire IM)

Concurrent Session 36:
Mechanisms and Treatment of Obliterative Bronchiolitis (Aqua 306)

Concurrent Session 37:
Broken Heart? We Can Offer a Second-Hand Pump (Indigo 202)

Concurrent Session 38:
Viral and Fungal Impacts after Lung Transplantation (Indigo 204)

9:30 am – 11:30 am
(Sapphire D)

11:30 am – Noon
Box Lunch Pick-up—Ticket Required (Sapphire Foyer)

11:45 am – 12:45 pm

Mid-day Symposium 9:
Great Debates in Cardiac Transplant Immunosuppression
(Sapphire D)

Mid-Day Symposium 10:
New Developments in the Anticoagulation for VADs (Sapphire AE)

Mid-Day Symposium 11:
Ethical Issues in Pediatric Cardiothoracic Transplant (Indigo 202)

Mid-Day Symposium 12:
Quandary at the Lung Transplant Board Meeting (Aqua 306)

Mid-Day Symposium 13:
Clinical Controversies in Pulmonary Hypertension: To Treat or Not To Treat? That Is The Question (Sapphire IM)

Mid-Day Symposium 14:
What Is It? Intriguing Cases in Heart Transplant Pathology (Indigo 204)

11:45 am – 1:00 pm

1:00 pm – 2:00 pm

Concurrent Session 39:
How Do VADs Impact Our Decisions on Transplant? (Sapphire D)

Concurrent Session 40:
Lining Up Risks: Pre-transplant Priority and Risk Assessment: Cardiac (Sapphire AE)

Concurrent Session 41:
Lung Transplantation—Surgical Issues (Sapphire IM)

Concurrent Session 42:
Ischemia Reperfusion Injury (Aqua 306)

Concurrent Session 43:
Junior Faculty Case Reports
Challenges in Heart Transplantation and Mechanical Circulatory Support
(Indigo 202)

Concurrent Session 44:
Pediatric Heart and Lung Transplant—Outcomes and Complications (Indigo 204)

2:15 pm – 4:40 pm

5:00 pm – 10:00 pm

Contributing Writers:

Lars Burdorf, MD and
Zachary Kon, MD

Newsletter Contact:
Lauren Daniels


31st Annual Meeting & Scientific Sessions
◊ San Diego ◊

Saturday, April 16, 2011
Volume 7, Issue 4
Printer Friendly PDF

How to Change Your LVAD Battery While Driving a Car

      Left ventricular assist device implantation has become a routine treatment option for many patients suffering from end stage heart failure. Still, the concern about reduced quality of life—due to drugs (e.g. anti coagulants), percutaneous drive lines, and the dependence on a power connection or charged battery—remains, despite of all medical and technical progress and inventions.
      In Friday's session, "Collaborating to Promote and Enhance QOL in End Stage Organ Disease," which Drs. Samantha J. Anthony and Michael G. Petty chaired, some interesting and valuable studies concerning VAD patients were presented.
      Dr. C. Kugler from Hannover Medical School, Germany, discussed the importance of patient counseling following implantation of the assist device. In the German study, dietary intervention, physical conditioning and psychosocial support resulted in a strong positive effect on the patient's weight management, exercise tolerance and on fighting anxiety when compared to a noncounseled patient cohort.
      For many patients, driving a car is a major factor of quality of life. So far, no clear guidelines or recommendation have been stated to deal with this issue for LVAD patients. Dr. S. Emani, Ohio State University Medical Center, presented a retrospective study in which 24 LVAD patients with a valid driver's license were interviewed and asked for their current driving habits. Only 5 of those admitted that their doctor told them not to drive, 19 are currently driving with an LVAD. During the accumulated 438 month of LVAD treatment, no accidents were reported by the study participants. Interestingly, 3 patients had to change the LVAD battery while driving in the car.
      Yesterday's session offered insightful perspective on the patient's life after the patient leaves the hospital, which surgeons are not confronted with too often. It demonstrated the need for post-hospital stay professional guidance and illustrated the benefit that a patient can gain from it to improve his personal quality of life and remain an active, content individual.

Don't Miss Today's Closing Plenary
2:15pm in Sapphire D

This afternoon's Closing Plenary Session chaired by Drs. Stuart Sweet and Lori West will feature a Keynote Lecture, "Proteomics/Novel Diagnostics in Tranplantation," by Dr. Daniel Salomon of The Scripps Research Insitute in La Jolla, CA. Dr. Francis Delmonico, Harvard Medical School/Massachusetts General Hospital will discuss emerging public policy initiatives for promoting organ donation. Hear a summary of the meeting in "What's Hot and What's Cool" followed by a spirited "Supersize Me" debate regarding the proposition: "Obestity is NOT a Contraindication to Thoracic Replacement Therapy."

This issue of the conference coverage
newsletter was supported by a grant from:

astellas transplant

The Future of Thoracic Transplant Fast Approaching

      Yesterday's plenary session, "Gazing Into the Crystal Ball – Emerging Therapy in Thoracic Transplantation," was action-packed with five presentations looking into the future to predict emerging therapies in thoracic transplantation and allied technologies.
      The first presentation was by Dr. David S. Wilkes, who emphasized that immunosuppression is not a "one-size-fits-all," especially since baseline graft status affects the future development of acute chronic rejection. He predicted that we will develop tools that will potentially increase tolerance and can be used in conjunction with ex-vivo lung perfusion.
      Dr. Michael Huber then spoke about transplantation versus MCS as treatment for survivors of congenital heart disease. Although MCS is as successful as BTT, and likely to improve further in coming years, Dr. Huber stressed that currently transplantation is associated with the best outcomes.
      The session continued with Dr. Eduardo Marban, who presented, "Cell Based Alternatives to MCS: Reconstruction Ahead?" He reported that although many other cell lines have not lived up to the hype, cardiosphere-derived cells are showing significant promise with early results from the CADUCES trial.
      Potential ex-vivo therapies for organs were the topic of the next discussion by Dr. Shaf Keshavjee. He described how multiple etiologies of lung dysfunction could be corrected using this platform, and concluded his presentation with promising preclinical results for IL-10 gene therapy.
      Dr. Joseph B. Zwischenberger finished out the session with review of how much better artificial pulmonary support has become, and predicted it will improve further in the near future based on simple predictable device improvements.

Drug Therapy for Pulmonary Hypertension in the Spotlight

      Three presentations of particular interest were included in Concurrent Session 21: Drug Therapy in Pulmonary Hypertension yesterday. The first study, presented by Dr. Bourge, evaluated the safety of transitioning from iloprost to treprostinil. The study was an open-label, prospective, multicenter trial of 73 patients. He concluded that the switch was well tolerated and was associated with maintenance of exercise capacity and improved quality of life.
      Quality of life was also the subject of Dr. Torres's study, "COMPASS-3: Quality of Life in Patients with Pulmonary Arterial Hypertension." The study was a prospective, open-label, multi-center trial investigating a bosentan-based, stepped approach to therapy. He presented that an improvement quality of life was seen after a 28 week Bosentan-based stepped therapy in patients with PAH.
      "Perioperative Sildenafil Administration Decreases the Risk of Early Death Due to the Transplanted Heart Right Ventricle Failure," presented by Dr. Maruszewski, concluded the session. This retrospective case-control study evaluated the effect of sildenafil on right ventricular failure-related mortality following heart transplantation. Although no difference in overall 30-day mortality or the incidence of right ventricular failure were seen between those who received or did not receive sildenafil, there was a statistically significant reduction in mortality associated with right ventricular failure.